Abstract
Neurotrophic factors comprise a broad family of secreted proteins that have growth promoting, survival promoting and differentiation inducing activities. Disruption of neurotrophic factor signalling is a characteristic of many central and peripheral nervous system disorders, such as Alzheimers disease, Parkinsons disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, and peripheral neuropathy and pain. It follows that treating patients with neurotrophic factors might be beneficial in a range of neurological diseases. However, the promising results seen in animal models of disease have not translated well into clinical trials due to the poor pharmacokinetics associated with the intact proteins, in particular, their short in vivo half-life, low blood brain barrier permeability, limited diffusion, and undesirable effects through multiple receptor interactions. This has been the main motivation for the design of small molecule modulators of the neurotrophic factor pathways. The review gives a brief survey of the various strategies to design mimetics that have been reported in the literature with special emphasis on the tandem repeat peptide agonist approach for BDNF/NT-4/5 and N-cadherin mimetics.
CNS & Neurological Disorders - Drug Targets
Title: Tandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics
Volume: 7 Issue: 1
Author(s): Gareth Williams, Gareth Williams, Francisco Molina-Holgado, Francisco Molina-Holgado, Patrick Doherty and Patrick Doherty
Affiliation:
Abstract: Neurotrophic factors comprise a broad family of secreted proteins that have growth promoting, survival promoting and differentiation inducing activities. Disruption of neurotrophic factor signalling is a characteristic of many central and peripheral nervous system disorders, such as Alzheimers disease, Parkinsons disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke, and peripheral neuropathy and pain. It follows that treating patients with neurotrophic factors might be beneficial in a range of neurological diseases. However, the promising results seen in animal models of disease have not translated well into clinical trials due to the poor pharmacokinetics associated with the intact proteins, in particular, their short in vivo half-life, low blood brain barrier permeability, limited diffusion, and undesirable effects through multiple receptor interactions. This has been the main motivation for the design of small molecule modulators of the neurotrophic factor pathways. The review gives a brief survey of the various strategies to design mimetics that have been reported in the literature with special emphasis on the tandem repeat peptide agonist approach for BDNF/NT-4/5 and N-cadherin mimetics.
Export Options
About this article
Cite this article as:
Williams Gareth, Williams Gareth, Molina-Holgado Francisco, Molina-Holgado Francisco, Doherty Patrick and Doherty Patrick, Tandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics, CNS & Neurological Disorders - Drug Targets 2008; 7 (1) . https://dx.doi.org/10.2174/187152708783885200
DOI https://dx.doi.org/10.2174/187152708783885200 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transcriptomics Study of Neurodegenerative Disease: Emphasis on Synaptic Dysfunction Mechanism in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options
Current Neuropharmacology Cation-Responsive MRI Contrast Agents Based on Gadolinium(III)
Current Inorganic Chemistry (Discontinued) Selecting Good ‘Drug-Like’ Properties to Optimize Small Molecule Blood-Brain Barrier Penetration
Current Medicinal Chemistry Expression and Function of the Endocannabinoid System in Glial Cells
Current Pharmaceutical Design A Novel Physico-Chemical Property Based Model for Studying the Effects of Mutation on the Aggregation of Peptides
Protein & Peptide Letters Challenges and Advances in Gene Therapy Approaches for Neurodegenerative Disorders
Current Gene Therapy Sirtuins as Possible Targets in Neurodegenerative Diseases
Current Drug Targets Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design Molecular Mechanisms Determining Opposed Functional States of Microglia
Current Neuropharmacology Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines
Current Drug Targets The Effect of Single and Double Acetylation of Lysine Residues on Structural and Dynamical Features of Human Splicing Factor TDP-43 - A Statistical Ensemble Analysis
Combinatorial Chemistry & High Throughput Screening Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer’s Disease
Current Pharmaceutical Design Models of Parkinson’s Disease with Special Emphasis on Drosophila melanogaster
CNS & Neurological Disorders - Drug Targets The Role of Inflammation in Neurological Disorders
Current Pharmaceutical Design Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Progress of Computer-Aided Drug Design (CADD) of Proteasome Inhibitors
Current Topics in Medicinal Chemistry